LUMENIS smart532 - A.4.1. Parameters in continuous waveform (CW)

Clinical Guide Smart532
™
A-10 UM-1151440EN, Rev. C, May 2016
In CW, the stimulus is a single square pulse of duration 10-500 msec. The
appropriate power is usually found by titration: the power is initially set to
a low level and then increased gradually until the desired tissue effect is
obtained. Table A-1 lists recommended clinical treatment parameters for
intended medical conditions using CW pulse:
Table A-1: Recommended clinical treatment parameters in CW for intended medical conditions
Treatment
(Mode)
Power
(mW)
Required Tissue Reaction
Exposure
duration
(sec)
Spot size
(
µ
m)
Diabetic Retinopathy including
Macular Edema or Proliferative
Retinopathy
11
100-300
mild grey-white burn
0.05-0.5
50-200
Proliferative Diabetic
Retinopathy (PDR)
12,13
250-750
Whitening
0.02-0.1
100-500
Central Serous
ChorioRetinopathy (CSCR)
14
150-400
Light grayish
0.02-0.2
50-200
Macular Edema or Proliferative
Retinopathy associated with
Central Retinal Vein Occlusion
(CRVO) or Branch Retinal
Vein Occlusion (BRVO)
12
175-410
Grey-white
0.02-0.2
100-400
Retinal Tear
15
175-575
Grey-white
0.01-0.4
200-400
Iridotomy for angle closure
(Stretch)
16
500
Stroma at the iridotomy site
becomes thin and tense
0.2
500
Iridotomy for angle closure
(Penetration)
16
1000
Penetration , until a hole of
0.2 mm in the iris is formed
0.02-0.2
50
Trabeculoplasty for primary
open angle glaucoma
17
400-600
Blanching
0.1
50
CNV
18
200
Mild whitish
0.2
150-250
11
P. Romero-Aroca, J. Reyes-Torres, M. Baget-Bernaldiz and C. Blasco-Suñe, "Laser
treatment for diabetic macular edema in the 21st century,"
Curr. Diabetes Rev ., vol. 10, no.
2, pp. 100-12, 2014.
12
Y. Paulus and M. Blumenkranz, "Proliferative and nonproliferative diabetic retinopathy,"
One Network , 2013.
13
C. Sanghvi, R. McLauchlan, C. Delgado, L. Young, S. Charles, G. Marcellino and P. Stanga,
"Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures.,"
Br J
Ophthalmol
, vol. 92, no. 8, pp. 1061-4, 2008.
14
L. Ficker, G. Vafidis, A. While, P. Leaver, “Long-term follow-up of a prospective trial of
argon laser photocoagulation in the treatment of central serous retinopathy”,
Br J
Ophthalmol
, vol 72, pp. 829-34, 1988
15
M. Muqit, C. Sanghvi, R McLauchlan, C. Delgado, LB Young, SJ Charles, GR Marcellino and
PE. Stanga. “Study of clinical applications and safety for Pascal_ laser photocoagulation in
retinal vascular disorders”.
Acta Ophthalmologica 90:155-161, 2012
16
R. Harrad, K. Stannard and J. Shilling, "Argon laser iridotomy," Br J Ophthalmol , vol. 69,
no. 5, pp. 368-72, 1985.
17
E. Rosenfeld, G. Shemesh and S. Kurtz, "The efficacy of selective laser trabeculoplasty
versus argon laser trabeculoplasty in pseudophakic glaucoma patients,"
Clin Ophthalmol , vol.
6, pp. 1935-40, 2012.
18
L.V. Angioletti, P.J. Colquhoun, A.D. Kulik, E.H. Malpica , “Indirect photocoagulation of
subfoveal choroidal neovascularization in age-related macular degeneration”,
Bull N Y Acad
Med
, vol. 67(4), pp. 389-98, 1991
A.4.1. Parameters in
continuous
waveform (CW)